p53, a tumor suppressor gene, functioning as a transcription factor, has been recently shown in a cell free system to be subject to redox (reduction/oxidation) regulation. Oxidants or metal chelating reagents disrupt wildtype p53 conformation and decrease or abolish its DNA binding activity, while reductants restore wildtype conformation and increase DNA binding. We have extended these observations to intact cell systems by using luciferase transactivation assay in two murine tumor cell lines, both harboring endogenous wildtype p53. The results showed that none of these in vitro active reagents, except 1,10-phenanthroline (OP) has a signi®cant eect on p53 transactivation activity. OP, a metal chelator and p53 inactivator in cell free systems, however, induces p53 transactivation activity as well as sequence-speci®c DNA binding in a dose dependent manner. OP also dierentially induces endogenous expression of several known p53 target genes such as Waf-1 and Mdm-2, but not Bax, Gadd45, and PCNA. Increased p53 activity induced by OP is not due to elevated p53 mRNA nor to protein levels. Furthermore, the OP-induced p53 transcriptional activation is not due to its potential DNA intercalating activity, but mainly due to its metal chelating activity. OP was also found to induce dramatically apoptotic cell death in these tumor cells harboring wildtype p53, to a less extent in MEF cells from p53 knockout mice and not at all in Saos-2 cells without p53 or Rb. We concluded from this study that (a) unlike what has been seen in vitro, OP induces p53 activity in intact cells (b) OP activates p53 transcriptional activity without increasing p53 protein; and (c) activation of p53 may contribute to apoptosis, but is not required.
Introduction
Human p53 is a 393-amino acid nuclear phosphoprotein, functioning as a transcription factor. It forms homotetramers through an oligomerization domain in its carboxyl terminus, speci®cally binds to its consensus binding site (two motif of 5'-PuPuPuC(A/T)(T/A) GPyPyPy-3') through a speci®c DNA binding domain in the center portion of the molecule, and transactivates or represses downstream target genes through its transactivation domain in the amino terminus (Lane, 1994; El-Deiry et al., 1992) . As a typical tumor suppressor gene, p53 has shown to inhibit tumor cell growth and suppress transformation (Baker et al., 1990) . As a`genome guard', p53 induces G 1 arrest/ apoptosis and prevents gene ampli®cation (Kastan et al., 1995; Hartwell, 1992; Selivanova and Wiman, 1995) . Most of p53 functions involve p53 activity as a transcription factor. The p53 mutations found in many human cancers were clustered in the speci®c DNA binding domain of the p53 molecule. This leads to inactivation of p53 function through abolishing p53 speci®c DNA binding and transactivation.
Like many other cysteine-containing transcription factors, such as AP-1 and NF-kB, p53 was recently found to be subject to redox regulation (see review by Sun and Oberley, 1996) . Milner and coworkers have systematically studied post-translational regulation of p53 conformation by redox, metals/metal chelators, salt and temperature using in vitro translated p53 protein (Hainaut and Milner, 1993a,b; Hainaut et al., 1995a,b; Butcher et al., 1994) . The concept was that if cysteines and zinc are important in stablizing the DNA-binding of p53, disruption of them by reductants/oxidants or metal chelators should abolish DNA binding activity. Indeed, they found that copper ion, the metal chelator 1,10-phenanthroline (OP), and oxidation (by diamide) all disrupt wildtype p53 conformation as detected by conformation-speci®c p53 antibodies, and inhibit its sequence speci®c DNA binding demonstrated by a mobility-shift assay. The reductant, 1,4-dithio-1-threitol (DTT) favors the folding of p53 into wildtype conformation and increases DNA binding (Hainaut and Milner, 1993a; Hainaut et al., 1995b) . DTT also restores p53 binding activity disrupted by diamide (Hupp et al., 1993) . Similar observations have been reported by others using metal chelators (OP and EDTA), the alkylating reagent N-ethyl-maleimide (NEM), the oxidant diamide and the reducing reagent DTT (Hupp et al., 1993; Srinivasan et al., 1993; Pavletich et al., 1993; Rainwater et al., 1995) . Removal of reducing agents by dialysis completely inactivated p53 DNA binding activity, suggesting the importance of a reducing environment in cells for active p53 protein (Hupp et al., 1993) . We have extended this in vitro observation to intact cell systems and report here that OP, a metal chelator and p53 DNA binding inactivator in a cell free system, activates p53 transcriptional activity without increasing p53 protein. Activation of p53 may contribute to cell death via apoptosis.
Results
Oxidants, reductants, antioxidants and many metal chelators, except OP did not signi®cantly change p53 activity in intact cells
In vitro test tube studies have recently shown that oxidation, metals and metal chelators, such as OP, can disrupt wildtype p53 conformation and inhibit seqeunce speci®c DNA binding, while the reductant 1,4 dithio-1-threitol (DTT) favors the folding of p53 into a wildtype conformation and increases DNA binding (Sun and Oberley, 1996; Hainaut and Milner, 1993a,b; Hupp et al., 1993; Pavletich et al., 1993) . To extend this in vitro observation to an intact cell system, we have used a transient transfection/luciferase reporter transactivation assay to assess in vivo p53 redox regulation. Several luciferase reporter plasmids driven by a p53 speci®c binding site derived from the mouse Mdm-2 gene, Waf-1 gene, or synthetic p53 binding site (PG13) (Juven et al., 1993; El-Deiry et al., 1993; Kern et al., 1991) were used for transfection. The recipient cells include L-RT101, a mouse JB6 tumor line, and HTx, a spontaneously transformed mouse liver line, both harboring endogenous wildtype p53 (Sun et al., 1993b,c) , and human Saos-2 cells, lacking endogenous p53 (cotransfected with wildtype p53 in this case) (Sun et al., 1993a) . Transient transfectants were then exposed to reductants (DTT, 1 mM; glutathione, GSH, 5 mM; or N-acetyl-L-cysteine, 5 mM) or oxidants (H 2 O 2 , 0.1 mM; paraquat, 0.5 mM; oxidized DTT, 2.5 mM; GSSG, 5 mM; or diamide 0.2 mM), to metals (zinc sulfate, 10 mM; cuprous chloride, 20 mM; p-chloromercurphenylsulfonic acid, 8 mM; or mercury chloride, 3 mM), or metal chelators (OP, 150 mM, dipicolinic acid, 150 mM; or diethylenetriamine-acetic acid, 50 mM), to compounds which inhibit endogenous GSH synthesis (L-buthionine sulfoximine, 10 mM), or simply to antioxidants (butylated hydroxy-anisole, 10 mM, or pyrrolidine dithiocarbamate 300 mM). Topoisomerase I inhibitor, camptothecin, (10 mM) and topoisomerase II inhibitor, etoposide, (10 mM), two known p53 inducers (Tishler et al., 1993; Whitacre et al., 1995) were used as positive controls. The drug concentrations used have shown no cytotoxicity in a period of at least 24 h. The results were shown in Figure 1a and b, where Mdm-2-luc was used as a reporter and L-RT101 cell as a recipient line. In contrast to the observations obtained in a cell free system, none of the above listed redox compounds, except OP, signi®cantly increased or decreased p53 transactivation activity. OP, an metal chelator and p53 inactivator in a cell free system, however, increased p53 activity by sixfold (Figure 1b) . Two positive controls, camptothecin or etoposide also increased p53 activity by two-to threefold (Figure 1a) . Similar results using these above-listed redox compounds were obtained when Saos-2 cells were used as recipients, cotransfected with wildtype p53 expressing plasmid along with PG13-luc or Waf-1-luc as reporter constructs. One exception is that some reductants (DTT, GSH) but not their oxidant forms decreased p53 transactivation activity by 30 ± 50% in Saos-2 cells (data not shown).
OP increases p53 transactivation activity and sequence speci®c DNA binding in two mouse tumor cells
Having observed that OP activates p53 transactivation activity in L-RT101 cells, we next examined the dosage dependence of this eect. As shown in Figure 2a , OP induced p53 transactivation in a dose dependent manner in L-RT101 cells. The p53 activity was increased up to twofold at an OP concentration of 25 mM and reached sixfold at 150 mM. The higher concentration (300 mM) was toxic to the cells. In H-Tx cells, however, OP treatment increased p53 activity by 2 ± 3-fold but was not dose dependent. We noticed that at concentrations of 100 mM or above, OP induced apoptosis remarkably in H-Tx cells. The lack of the dose a b Figure 1 Redox modulation of p53 activity as a transcription factor: Mouse JB6 epidermal tumor line (L-RT101) was transiently co-transfected with Mdm2-luc and CMV-gal constructs and treated with various redox(reductant/oxidant) compounds for 12 h followed by assay for luciferase and bgalactosidase activities as detailed in Materials and methods. The compounds include in (a) H 2 O 2 (0.1 mM), paraquat (Para, a superoxide generator, 0.5 mM), DTT (1 mM), oxidized DTT (ODTT, 2.5 mM), glutathione (GSH, 5 mM), GSSG (5 mM), diamide (Dad, 0.2 mM), N-acetyl-L-cysteine (NAC, 5 mM), camptothecin (Cam, 10 mM) or etoposide (Eto, 10 mM) and in (b) 1,10-phenanthroline (OP, 150 mM), dipicolinic acid (DA, 150 mM), diethylenetriamine-acetic acid (DET, 50 mM), zinc sulfate (Zn, 10 mM), cuprous chloride (Cu, 20 mM), mercury chloride (Hg, 3 mM), p-chloromercurphenylsulfonic acid, (CMPSA, 8 mM), L-buthionine sulfoximine (BSO, 10 mM), pyrrolidine dithiocarbamate PDTC, 300 mM), or butylated hydroxy-anisole (BHA, 10 mM). The results have been normalized with b-galactosidase activity. The error bars stand for standard error of mean from at least three independent transfections and drug treatments dependence at the high concentration may, therefore, re¯ect an induced cell death.
We have also tested whether increased p53 transactivation activity can be re¯ected by an increase in DNA binding. Indeed, as shown in Figure 2b , OP treatment (for 12 h) did increase DNA binding and the increase in DNA binding was dose dependent in both tumor lines. In L-RT101 cells, the p53 speci®c DNA binding was hardly seen even with the OP treatment at a concentration of 50 mM, which could be attributable to a low basal level of p53 (Sun et al., 1993c) . At a higher OP concentration (150 mM), p53 binding was revealed. Elimination of binding by excess cold probe (506) indicated a sequence-speci®c DNA binding. In H-Tx cells, basal p53 binding can be revealed due to its high expression level (Sun et al., 1993b) . The binding increased dramatically and dose-dependently after OP treatment. Addition of antibody, pAb421, enhanced p53 binding as well as caused band supershifting. The strong binding was only partially blocked with 506 excess of cold probe. The results indicate that OP increases p53 DNA binding in a dose dependent manner and that there is a dissociation between DNA binding and transactivation in H-Tx cells, since increased binding did not result in an increased transactivation (compare Figure 2a and b when 150 mM OP was used).
OP increases Waf-1 and Mdm-2 expressions
We have shown that OP induces p53 speci®c DNA binding and transactivation. We then investigated possible induction of several known p53 target genes, including Waf-1 (El-Deiry et al., 1993), Mdm-2 (Wu et al., 1993) , Bax (Miyashita and Reed, 1995) , Gadd45 (Kastan et al., 1992) and PCNA (Shivakumar et al., 1995; Morris et al., 1996) . As shown in Figure 3a , OP did induce Waf-1 expression in both tumor cell lines. The induction occurred as early as 1 to 2 h post treatment and reached a peak at 12 h. A stronger induction was seen in H-Tx cells, correlating with the stronger DNA binding seen in this line. OP also signi®cantly induced Mdm2 expression in both cell lines. The induction occurred a little later (6 h post treatment), compared to Waf-1 and an elevated level persisted up to 24 h ( Figure 3b ). However, no signi®cant inductions of Bax, Gadd45, or PCNA expression can be seen ( Figure 3b ). We have performed densitometric quantitation of Bax expression after OP treatment and have found no signi®cant induction (less than 1.5-fold) after normalization with either 28S or 18S. These results indicate that OPactivated p53 preferentially induced endogenous expression of certain, but not all, target genes.
OP increases transcriptional activity of p53 neither through the accumulation of p53 mRNA nor p53 protein
We next investigated the possible mechanism by which p53 activity was induced. We performed Northern analysis and found that increased p53 activity was not due to the increased mRNA level (Figure 4a ). OP (150 mM) treatment did not signi®cantly change p53 mRNA level up to 12 h, when signi®cant activation of p53 binding and transactivation was seen. We have also examined whether increased activity is due to increased protein levels resulting from an increased stability or due to the change of p53 conformation. As shown in Figure 4b , neither possibility turns out to be the case. The drug treatment did not cause detectable change in p53 protein level nor in p53 conformation as measured by p53 antibody pAb421 (detecting both wildtype and mutant conformation, Figure 4b ), pAb240 (detecting mutant conformation only, not shown), or pAb246 (detecting wildtype conformation, not shown). When using pAb421 for Western blot analysis, we did not see any time (1, 2, 6, 12 h) or dose (50, 100, 150 mM)-dependent change of p53 protein level after OP treatment (data not shown). Finally, we
Figure 2 OP induces p53 transactivation activity and sequence speci®c DNA binding: Mouse JB6 epidermal tumor line (L-RT101) and spontaneously transformed liver line (H-Tx) were transiently transfected with Mdm2-luc construct, treated with OP at the indicated concentration for 12 h and assayed for luciferase activity (a) or gel retardation (b) as described in Materials and methods. The results shown in (a) have been normalized with bgalactosidase activity (by co-transfection). Mean+standard error of mean was derived from six to eight independent transfections and OP treatments, except for 25 mM treatment where n=3. For gel retardation assay, p53 antibody pAb421 was included in some reactions (as indicated) to enhance p53 binding. The p53 (lower) and p53-Ab supershifted (upper) bands are indicated by the arrows. The band shown on the bottom of gel is free labeled probe. 506 excess of cold oligo was included (as indicated) to show the binding speci®city (Auld, 1988) . If OP functions solely as a metal chelator, OP-Fe 2+ complex or other non-metal chelating OP compounds, such as 1,7-OP and 4,7-OP should have no p53 activating activity. As shown in Figure 5a , activation of p53 transcriptional activity was dramatically decreased (up to two-to threefold) when all three compounds without metal chelating activity were used. But all those compounds still retain some activity in activating p53 (two-to threefold induction). The results showed that OP-induced p53 activation is mainly due to metal chelating activity, but other non-metal chelating activity may also contribute to the induction.
By structure, OP has the capacity to intercalate DNA. DNA intercalation may lead to DNA damage which could activate p53 as shown in many anticancer drugs (Lowe et al., 1993) . We have performed ethidium bromide (EtBr) displacement assays to evaluate DNA intercalating activity of OP at the concentration used for p53 activation. As shown in Figure 5b . OP at a maximum p53 activation concentration (150 mM) caused 35% displacement of EtBr binding to DNA, which is indistinguishable from that of 1,7-OP and 4, 7-OP serving as controls for both p53 activation and DNA intercalating activities. A similar level of EtBr displacement was also seen in another metal chelator, dipicolinic acid (data not shown), which has no p53 activation at all (Figure 1b At this concentration, PD115934 did not induce p53 transactivation activity (data not shown), but did cause more than 50% EtBr displacement (Figure 5b ). The data demonstrated that OP induced p53 transcriptional activity may not result from its potential DNA intercalating activity at the concentration used.
OP induces apoptosis which does not require p53
What is the biological outcome of p53 activation followed by Waf-1/Mdm-2 induction? A cell type dependent G 1 arrest or apoptosis has been observed following DNA damage-induced p53/Waf-1 activation (Kastan et al., 1995; Liebermann et al., 1995) . We found that prolonged treatment of OP (up to 24 h) induces cell shrinkage and detachment and this was more obviously seen in H-Tx cells (data not shown). A DNA fragmentation experiment was therefore conducted to de®ne the nature of cell deaths. As shown in Figure 6 , a DNA fragmental ladder, characteristic of apoptosis, was seen following 12 h OP treatment (upper panel) and was more remarkable after 24 h treatment (bottom panel) in two murine tumor lines, harboring endogenous wildtype p53. A dose-dependent formation of DNA laddering was seen in L-RT101 cells, but not in H-Tx cells, correlating with transcriptional activity measured by the luciferase reporter assay. DNA ladder formation was more obviously seen in H-Tx cells, correlating with morphological observations. To de®ne whether OP-induced apoptosis is mediated through and/or requires p53 activation, we examined possible induction of apoptosis in two p53 negative cell lines, mouse embryo ®broblast from p53 knockout mouse and human Saos-2 cells, following OP treatment. Our rationale is that if p53 activation is required for apoptosis, cell lines without the p53 gene should not undergo apoptosis after exposure to OP. Two p53 negative cell lines, MEF from p53 7/7 mouse a b Figure 5 Metal chelating but not DNA intercalating activity accounts mainly for OP-induced p53 activation: (a) Other nonmetal chelating OP compounds were tested for their ability to activate p53 transcriptional activity. The luciferase assay was conducted as described in Figure 1 legend. n=8 for 1,10-OP treatment, and n=3 for 1,7-OP, 4,7-OP or 1,10-OP-Fe and Saos-2 cells, were exposed to OP at various concentrations up to 24 h and no morphological appearance of apoptosis can be observed (data not shown). These cells were then subjected to a DNA fragmentation assay and results were shown in Figure  7 . In MEF cells, a minor DNA ladder was formed 12 h post treatment only when a high OP concentration (150 mM) was used. Prolonged OP treatment (24 h) did, however, cause the ladder formation in all concentrations used, although the degree of DNA fragmentation is much less severe, compared to p53 positive lines (Figure 7 , upper panel, compared to Figure 6 ). In Saos-2 cells, in which both the p53 and Rb genes were deleted, no DNA fragmentation was seen regardless of drug concentration and exposure time (Figure 7 , bottom panel). The results suggested that (a) although p53 activation may contribute to induction of apoptosis, it is not required in this process; and (b) status of Rb may also play a role in determination of cellular apoptotic death.
Discussion
The major ®ndings of this report are that (1) OP, a typical metal chelating reagent, can activate p53 transcriptional activity without increasing p53 protein and (2) this activation may contribute to cellular death via apoptosis. Activation of p53 activity is evident by (a) increased transactivation; (b) increased speci®c DNA binding; and (c) increased expression of some endogenous p53 target genes including Waf-1 and Mdm-2. In contrast to observations made in a cell-free system, p53 in intact cells is not subject to regulation by redox, metals, and metal chelators with an exception of OP. The apparent discrepancy between in vitro (cell-free system) and in vivo (intact cells) experiments could mainly result from two factors: (1) in in vitro assays, redox compounds interact directly and solely with puri®ed p53 protein, while in in vivo experiments, the compounds must enter the cells, travel to nucleus and then interact with the target molecules.
In vivo experiments involve the number of molecules entering cells, whether they have been metabolized/ modi®ed before reaching and interacting with the targets, and the ®nal concentration of unmetabolized compounts, if any, left to interact with the target molecules; (2) related to #1, antioxidants which scavenge radicals (Sun, 1990) are present in vivo but not in vitro. It is worth noting that the OP concentration used in the in vitro assay (showing p53 inactivation, Hainaut and Milner, 1993a) was ®ve-to 10-fold higher than what we used in intact cells (625 to 1250 mM vs 150 mM maximum). A high concentration may be needed to chelate in vitro a tetrahedrally coordinated zinc atom which stabilizes the p53 looping structure (Cho et al., 1994) .
How does OP activate p53 in intact tumor cells? We have excluded the possibility that OP acts as an active DNA intercalating reagent to cause DNA damage which eventually activates p53 by increasing p53 protein levels. High p53 activating activity with metal chelating 1,10-OP and low such activity with non-metal chelating OP compounds, 1,7-OP or 4,7-OP or OPFe 2+ complex indicate that metal chelating activity of such compounds accounts for most of the p53 activating activity. It is well known that Fe 2+ chelating can reduce/prevent toxic hydroxyl radical formation by the Fenton reaction (Halliwell and Gutteridge, 1989) . Since hydroxyl radicals have been shown to damage DNA, lipids and proteins (Sun, 1990) , reduction of its formation by iron chelator, 1,10-OP may free p53 from hydroxyl radical damage, thus favoring p53 to adopt a wildtype conformation. Alternatively, metal ions such as zinc were found to be required for formation of stable p53-large T antigen complex in vitro (Kernohan et al., 1996) . It is speculated that chelating out metals by OP may release p53 from binding with some cellular inhibitory proteins, thus restoring its activity.
One interesting observation reported here is that, in contrast to radiation-induced p53 activation by which p53 protein level was elevated (Kastan et al., 1991) , OP increases p53 transcriptional activity without increasing the levels of the p53 mRNA or p53 protein. A similar observation has been made in senescing ®broblasts (Atadja et al., 1995) . Three microtubule-active drugs have also been shown to increase transcriptional activity of p53, although the authors have not provided direct demonstration that p53 protein was not increased (Tishler et al., 1995) . The underlying mechanism of this is not clear at the present time. It suggests some form of post-translational activation of p53 function. The observation made here should also serve as a cautious note for the apoptosis inducing Saos-2 Figure 7 Prolonged OP treatment also induces apoptosis in p53 7/7 MEF cells, but not in p53-/Rb-human Saos-2 cells: Subcon¯uent MEF (top panel) and Saos-2 (bottom panel) cells in 100 mm dish were subjected to OP treatment at various concentrations for up to 24 h. Both attached and detached (hardly seen) cells were harvested for DNA fragmentation assays as detailed in Materials and methods. 100 bp and 1 kb marker (m) were used for size determination compounds. The therapeutic compounds that induce apoptosis without inducing p53 protein level may still function via a p53 dependent pathway by increasing p53 transcriptional activity.
Another dierence in p53 activation between OP and radiation treatment is the induction of known p53 target genes. OP-activated p53 preferentially induces Waf-1 and Mdm-2 expression, but not other p53 eector genes, including Bax, Gadd45, and PCNA, whereas radiation-induced p53 activates the expressions of Waf-1, Mdm-2, Gadd45 and Bax (Kastan et al., 1995; Zhan et al., 1994) . The outcome of ionizing radiation induced p53 is G 1 arrest in ®broblasts and RKO colorectal carcinoma cells and apoptosis in lymphoid-originated cell lines (Kastan et al., 1995) . Here using two epidermal/epithelial originated tumor lines, we showed that OP-induced p53 activation may contribute to the induction of apoptosis, although p53 may not be required for this process. How p53/Waf-1/ Mdm-2 activation contributes to apoptosis is a subject of future investigation. Our observation may, nevertheless, link the damage-induced p53 pathway to novel, as yet unidenti®ed signal-transduction cascades that detect metal-related cellular perturbations.
Although the degree of apoptotic death in p53 negative MEF cells is much less severe and requires prolonged treatment, OP did induce apoptosis in both p53 positive as well as negative cells. The fact that OP was not able to induce apoptosis in p53-/Rb-Saos-2 cells strongly suggests Rb as a key determinant of growth arrest and apoptosis (Haner and Oren, 1995; Ko and Prives, 1996) . OP has been previously shown to induce apoptosis in thymocyte or leukemic lines by increasing cell surface APO-1/Fas ligand expression (Mariani et al., 1995) or by chelating Zn 2+ (Adebodun and Post, 1995; Hughes and Cidlowski, 1994; Zalewski et al., 1991) . OP also suppressed apoptosis induced by etoposide, an inhibitor of DNA topoisomerase II in HL-60 cells or thymocytes (Bessho et al., 1994; Abello et al., 1994) . In endothelial cells, OP suppresses apoptosis triggered by hydroxyl radical by its Fe 2+ chelating activity to prevent the radical formation through the Fenton reaction (Bessho et al., 1994; Abello et al., 1994) . The data shown here may suggest another mechanism by which OP induces apoptosis in epidermal/epithelial originated cells, that is, activation of p53 and requirement of Rb. It is therefore of great interest to isolate and characterize p53/Rb downstream target genes responsible for the apoptosis induction. This is currently an ongoing project in our laboratory.
Materials and methods
Cell culture, DNA transfection and luciferase assay
The mouse epidermal JB6 tumor line, LRT-101; a spontaneously transformed mouse liver line, H-Tx; mouse embryo ®broblast from p53 knockout mouse, p53 7/7 MEF; and the human Saos-2 line were grown in 5% EMEM (for LRT101) or 10% DMEM with high glucose, respectively. For transfection, single suspended cells were seeded into 24-well plates at a cell concentration of 10 5 per well 24 h prior to transfection. Several luciferase reporter plasmids driven by a p53 speci®c binding site derived from the mouse MDM-2 gene, Waf-1 gene or the synthetic p53 binding site (PG13) (Juven et al., 1993; ElDeiry et al., 1993; Kern et al., 1991) were used. They were co-transfected with a b-galactosidase construct, and in the case of human Saos-2 cells, also cotransfected with a wildtype p53 expression construct (pVcos7-p53) (Sun et al., 1993a) . The transient transfection was performed using the calcium phosphate method with a transfection eciency of 10 ± 15% as determined by b-galactosidase staining. For a 24-well plate, the amount of DNA used for each construct was 12 mg for b-gal, 33 mg for luciferase reporter or 15.5 mg of luciferase reporter plus 15.5 mg of pVcos-7-p53 (in the case of human Saos-2) in a total volume of 657 ml H 2 O. Ninety-three ml of 2 M CaCl 2 was added dropwise and incubated at room temperature for 10 min. The total 750 ml of DNA-CaCl 2 mixture was dropwise added into another tube containing 750 ml of 26 HEPES-Buered Saline (106 HBS contains 8.18 g of NaCl, 5.94 g of HEPES and 0.2 g of Na 2 HPO 4 in 100 ml H 2 O, pH 6.88) and incubated at room temperature for 15 min. Sixty-two ml of DNA-calcium precipitate was added into each well (containing 1 ml medium) in a 24-well plate and incubated at 378C for 6 ± 8 h. Cells were then washed 26 with PBS and cultured for 36 h before 12 h drug treatment was conducted. For each drug treatment, duplicate wells were used. Cells were rinsed with PBS 26 post drug treatment and lysed in the wells with 100 ml lysis buer from the luciferase assay kit (Promega, Madison, WI). An aliquot of cell lysate (10 ± 20 ml) was used to assay for luciferase activity as described (Sun et al., 1995) . Another aliquot (2 ± 5 ml) was used to measure b-galactosidase activity using the Galactor-Light chemiluminescent assay kit (Tropix, Inc, Bedford, MA). The transfection eciency was normalized with b-gal activity.
Gel retardation assay
The synthetic oligo of p53-binding consensus sequence (5'-AGACATGCCTAGACATGCCT-3') was annealed and labeled with 32 P using T4 polynucleotide kinase and [g-32 P]ATP. Nuclear extracts were prepared from confluent H-Tx and L-RT101 cells treated with various concentrations of OP for 12 h as follows: cells were trypsinized, washed with phosphate buered saline and lysed in cold lysis buer (25 mM HEPES, pH 7.8, 50 mM KCl, 0.5% NP-40, 1 mM PMSF, 10 mg/ml leupeptin, 20 mg/ml aprotinin and 100 mM DTT) for 5 min. After washing once with the lysis buer without NP-40, the pellet was resuspended in cold Extraction Buer (25 mM HEPES, pH 7.8, 500 mM KCl, 10% glycerol, 1 mM PMSF, 10 mg/ml leupeptin, 20 mg/ml aprotinin and 100 mM DTT) and incubated on ice for 20 min with frequent mixing followed by spinning at 14 000 r.p.m. for 5 min. The supernatant was then saved as the nuclear extract. Protein concentrations were determined using the Bio-Rad Protein Assay Kit. A DNA-binding reaction mixture of 20 ml contained 20 mM Tris-HCl, pH 7.5, 4% Ficoll-400, 2 mM EDTA, 0.5 mM DTT, 1 mg poly (dI/dC), 32 P-labeled oligo (20 000 c.p.m.) was incubated with 1 mg of proteincontaining nuclear extract. In some experiments, the p53 antibody, pAb421 (Oncogene Science, 2 ml), was included, to increase DNA binding. To determine the binding speci®city, 506 excess of cold oligo was included in some reactions. The mixture was incubated at room temperature for 45 min and then loaded onto a 3.5% polyacrylamide gel. The gel was run in 0.56 TBE buer at 60 V, dried, and exposed to a Kodak ®lm overnight.
Ethidium bromide displacement assay
The relative anity of OP for DNA binding was determined by its ability to reduce¯uorescence of an ethidium bromide-DNA complex as described previously (Fry et al., 1985) . The drugs used were 1,10-OP, 1,7-OP, 4,7-OP, PD115934 (pyrazolo [3,4,5-kl] acridine-2(6H)-propanamine, 9-methoxy-N,N-dimethyl-5-nitro-methanesulfonate, as a positive control), and DMSO as a solvent control. A buer blank (9.4 mM NaCl, 20 mM EDTA and 2 mM HEPES) was subtracted from all measurements.
Immunoprecipitation assay
The level of p53 protein and its phosphorylation status after OP treatment were measured by immunoprecipitation of labeled cell lysates as described (Sun et al., 1993a,b,c) . Brie¯y, subcon¯uent cells were treated with various concentrations of OP for 9 h and subjected to phosphate or methionine starvation for 1 h and metabolically labeled with either [
32 P]orthophosphate (0.5 mCi/ml) or 35 S-translabel (0.2 mCi/ml) for 2 h in the presence of OP (total period of time for OP treatment is 12 h). Cells were then lysed on ice for 30 min in a lysis buer and spun at 12 000 g. The equal TCA precipitable radioactivity in the supernatant (3610 6 for [ 32 P] and 3610 7 for [ 35 S]) was immunoprecipitated using p53 antibodies (pAb421, pAb 240, or pAb246, Oncogene Science). The immunoprecipitates were then collected, washed and analysed on a 10% SDS-polyacrylamide gel. The gel was dried and exposed to X-ray ®lm.
Northern analysis
Northern analysis was performed as described previously (Sun et al., 1992) . The probes used were Waf-1, Mdm-2 (see Sun et al., 1995) , Gadd45, Bax from mouse cDNA, and PCNA from human cDNA, generated by RT ± PCR as described (Sun et al., 1993c) . The primers were designed based upon published sequences (Papathanasiou et al., 1991; Oltvai et al., 1993; Almendral et al., 1987) ¯anking the entire open reading frame. The PCR fragments with expected sizes were gel-puri®ed, subcloned and sequenced, and then used as probes.
DNA fragmentation assay
Subcon¯uent cells (80%) were treated with OP at various concentrations for 12 or 24 h. Both detached and attached cells were harvested by scraping with a rubber-policeman. Cells were collected by centrifugation and lysed with a lysis buer (5 mM Tris-Hcl, pH 8; 20 mM EDTA; 0.5% Triton X-100) on ice for 45 min. Fragmented DNA in the supernatant of a 14,000 r.p.m. centrifugation (45 min at 48C) was extracted 26 with phenol/chloroform and once with chloroform and precipitated by ethanol and salt. The DNA pellet was washed once with 70% ethanol and resuspended in TE buer with 100 mg/ml RNase at 378C for 2 h. The fragmented DNA was separated in 1.8% agarose gel electrophoresis and visualized under u.v. light.
Abbreviations OP, 1,10-phenanthroline; L-RT101, mouse JB6 epidermal tumor cells; H-TX, spontaneously transformed mouse liver cells; Mdm-2, mouse double minute-2; Waf-1, wildtype p53 activation fragment-1; Gadd45, growth arrest and DNA damage inducible gene 45; Bax, Bcl-2 associated X protein; PCNA, proliferating-cell nuclear antigen; MEF, mouse embryo®broblast
